Observational studyHeart and vessels2025
Factors associated with recurrence after drug-coated balloon therapy for femoropopliteal in-stent restenosis.
Observational study in Heart and vessels, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Impact of 1-month dual antiplatelet therapy after treatment with drug-coated balloon for femoropopliteal artery disease.Heart and vessels · 2026Article
- Paclitaxel distribution assessment after drug-coated balloon treatment in the superficial femoral artery: SNOW grade.Heart and vessels · 2026Article
- Insights on factors associated with recurrence after drug-coated balloon therapy for femoropopliteal in-stent restenosis.Heart and vessels · 2026Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the impact of intravascular ultrasound (IVUS)-evaluated tissue morphology on recurrence following drug-coated balloon (DCB) angioplasty for the treatment of femoropopliteal in-stent restenosis (FP-ISR).
methodsThis study was a single-center, retrospective, observational study. Study subjects were 65 FP-ISR lesions (mean lesion length: 165 ± 88 mm, occlusive restenosis: 25%) in 53 patients (age: 76 ± 8, diabetes mellitus: 66%) who underwent DCB angioplasty and whose IVUS data of tissue morphology were available. The morphology of ISR was determined by dominant tissue and classified into two group with and without fibrous tissue. Fibrous tissue was defined as the absence of calcification, equal to or more advanced than the echo luminance of the outer membrane, but without acoustic shadow. The outcome measure was recurrence-ISR, and cox proportional hazards models were used to explore factors associated with recurrence-ISR.
resultsDuring mean follow-up period of 16 ± 12 months, recurrence-ISR was found in 32% (n = 21). The tissue morphology of FP-ISR before DCB angioplasty was distributed with 68% (n = 44) in fibrous tissue group and with 33% (n = 21) in non-fibrous tissue group. Factors associated with recurrence-ISR were drug-eluting stent (DES)-ISR (hazard ratio [HR]: 4.329; 95% confidence interval [CI]: 1.572-11.918, P = 0.005) and non-fibrous tissue (HR: 4.595; 95% CI: 1.484-14.228, P = 0.008).
conclusionThe current study revealed IVUS-evaluated tissue morphology and DES-ISR lesions were significantly associated with recurrence FP-ISR after DCB angioplasty.
Indexed as
Identifiers
39556199What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.